• The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate properties comparable to the best in scientific literature to date
• D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors
• D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, with more than 210 issued U.S. patents, and has published more than 100 peer-reviewed papers in leading scientific journals

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced notable progress in its development of high-coherence qubits, with results expected to have a significant impact on its future quantum technologies. The fluxonium qubits that D-Wave has designed, manufactured, and operated demonstrate quantum properties comparable to the best in scientific literature to date.

The fluxonium qubit was pioneered by Michel Devoret and his colleagues at Yale University in 2009 and has recently become an attractive candidate for use in next-generation gate model quantum computing architectures. With the industry’s growing interest and D-Wave’s expertise in flux-like quantum technologies, the company explored the use of fluxonium in developing its own technology. D-Wave has manufactured and tested fluxonium qubits in a two-dimensional circuit geometry, measuring several factors.

“These results show that fluxonium is a viable candidate qubit for D-Wave’s gate model quantum computing architectures. Moreover, in doing this work, we have learned that fluxonium can address some of the known shortcomings of competing superconducting gate model qubits,” said Mark Johnson, SVP of quantum technologies and systems products at D-Wave (https://ibn.fm/icFXs). “We believe this will have a significant impact on D-Wave’s hardware development and reinforces our technical leadership by demonstrating that we can design, manufacture, and operate high-coherence fluxonium qubits that are comparable to the best in the world.”

We expect that quantum computing will have broad applicability to computationally complex problems across industries, including manufacturing, life sciences, finance, logistics, and more. D-Wave’s pursuit of practical quantum computing has resulted in its technology being used by more than two dozen Forbes Global 2000 companies and blue-chip industry leaders like Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin.

D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios. The company has more than 210 issued U.S. patents and has published more than 100 peer-reviewed papers in leading scientific journals.

According to data from Hyperion Research, over 80% of enterprises are looking to move forward with quantum computing efforts with increased funding and resources. One-third of respondents plan to invest at least $15 million in quantum efforts – all of which will take place in the next two to three years (https://ibn.fm/K387s). We believe this shows that forward-thinking organizations are beginning to recognize quantum as an opportunity to enhance operations – from finding efficiencies and reducing waste to decreasing time to solution and solving problems that were once abandoned due to their complex nature.

D-Wave is strategically positioned to help its customers achieve value by leveraging quantum computing in practical business applications, due to its use of annealing quantum computers. As one of the few companies offering a full stack of quantum computing systems, software, and services, D-Wave is making strides to enable enterprises, governments, developers, and researchers to access the power of quantum computing, which is a unique attribute for prospective investors.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding expectations of how the results of D-Wave’s progress with fluxonium qubits may impact its future quantum technologies and hardware development, including its gate model program; the conclusion that fluxonium may be a viable candidate qubit for D-Wave’s gate model quantum computing architectures; the broad applicability that quantum computing is expected to have to computationally complex problems across industries; the probability that enterprises will invest in quantum computing and the expected amount of such investments; and the ability of quantum computing to help businesses achieve value and to surpass their competition. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the results of further development of fluxonium qubits by D-Wave; the development by other companies of fluxonium qubits that may surpass D-Wave’s technology; the viability of fluxonium qubits as candidates for D-Wave’s gate model quantum computing architectures; the success of fluxonium qubits in gate model quantum computing architectures, if chosen for such purposes; whether fluxonium continues to address some of the known shortcomings of competing superconducting gate model qubits; general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on the company’s business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that D-Wave may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that the company’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. The company undertakes no duty to update this information unless required by law.

• Mexico has become the United States’ leading international trading partner in recent months amid the country’s ongoing trade war with China
• Coincidental with Mexico’s growth as a nearshore commercial trade partner, the port at Laredo, Texas has become the most lucrative hub for cross-border commerce, recording $28.1 billion during this year’s first quarter
• Freight Technologies (aka Fr8Tech) is dedicated to aiding cross-border commerce through a suite of technological solutions targeting the relatively unorganized cross-border shipping and carrier industry
• Fr8Tech’s flagship platform, Fr8App, draws on artificial intelligence and machine learning technology to help match loads optimally and monitor shipments from origin to final destination

The ongoing trade war between the United States and China is leading to a shift in international commerce sourcing that is manifest in changes to the volume of trade traffic at the United States’ shipping and transport gateways.

U.S. Census Bureau data analyzed by media organization WorldCity and in turn reported last month by FreightWaves.com (https://ibn.fm/wXWD5) indicates that Mexico has been the lead trading partner for the United States during five of the past six months, and that the shift toward nearshoring of automotive parts and vehicles, in particular, has driven the trend.

Mexico’s ascendance as a trading partner coincides with the port at Laredo, Texas emerging as the nation’s most lucrative commercial transfer hub among the nation’s 450 international gateways for trade. FreightWaves reported total commerce through Laredo grew 7.4 percent YOY to $28.1 billion, marking the fourth straight month it has exceeded traffic at the Port of Los Angeles and Chicago’s O’Hare International Airport.

Supply chain innovator Freight Technologies (NASDAQ: FRGT) has steadily expanded its technological platform for aiding cross-border commercial freight transportation networks within the United States-Mexico-Canada Agreement (“USMCA”) trade area formerly known as NAFTA.

Freight Technologies’ flagship solution, Fr8App, was released in its first commercial iteration shortly before the U.S.-China Trade War began in January 2018 over concerns that China was conducting intellectual property theft of U.S. technologies and engaging in “unfair trade practices” (https://ibn.fm/kA1Og).

Fr8App’s products package focuses on the relatively unorganized cross-border commercial freight market on the U.S.-Mexico border, and by extension, the U.S.-Canada border — growing to provide freight-matching and origin-to-destination monitoring services for shippers and carriers that draw on artificial intelligence (“AI”) and machine learning technology (https://ibn.fm/s0hbA).

In recent months, the company integrated an extensive new pool of truck drivers from automated booking solutions platform Trucker Tools’ network of over 315,000 carriers (https://ibn.fm/Zv3bl) and celebrated a contract renewal by multinational insulation manufacturing company K-FLEX that expects to have over 100 trucks per week transporting its products from Mexico to the United States, using Fr8App to help manage the shipments (https://ibn.fm/tP3t2).

“Mexico’s expanding manufacturing base has offered an alternative to producing in China. … The automotive industry is an especially active example of the cross-border manufacturing relationship,” Federal Reserve Bank of Dallas senior business economist Luis Torres told FreightWaves. “A U.S. plant typically produces an intermediate good that is then exported to Mexico where it becomes part of the assembly process before a final good is then imported back into the U.S.”

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.app.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds
• The company intends to use the net proceed from the offering for, among others, research and development
• On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets
• This strategic approach is expected to shorten development timelines, reduce the budgetary requirements, and increase probability of drug approval
• The company has also expanded into the CDMO business to plug an existing gap in the market, raising recurring revenue as a result

Biopharmaceutical company Scinai Immunotherapeutics (NASDAQ: SCNI) recently raised $1.33 million in gross proceeds from its previously announced registered direct offering of 1,146,522 of its American Depositary Shares (“ADSs”) (or ADS equivalents), which closed September 19. Moreover, in a concurrent private placement, the company issued unregistered warrants to purchase up to 1,146,522 ADSs representing ordinary shares. Each ADS represents 400 ordinary shares and was available at a purchase price of $1.16 per ADS (or ADS equivalent). Scinai intends to use the net proceeds from the offering for, general working capital, general corporate purposes, and research and development (“R&D”) (https://ibn.fm/ccWGG).

The company, which is focused on developing, manufacturing, and commercializing biological products for the treatment of autoimmune and infectious diseases, has in the recent past directed its R&D efforts toward the development and eventual commercialization of novel, innovative alpaca-derived nanosized antibodies (“NanoAbs”), also known as VHH-antibodies.

These efforts are rooted in a strategic research collaboration agreement between Scinai Immunotherapeutics and the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (“MPI”), and the University Medical Center Göttingen (“UMG”), both in Germany for the development of the NanoAbs. Based on the agreement, Scinai has an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb (https://ibn.fm/CV5XI).

The company recently exercised the exclusive option, signing an exclusive license agreement for the development and commercialization of a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis. Scinai is aggressively advancing the NanoAb preclinical development with the expectation that the IL-17 NanoAb will potentially enter clinical testing in 2024, with ex vivo proof-of-concept studies expected later this year (https://ibn.fm/OPSAU).

NanoAbs exhibit multiple valuable competitive advantages over existing monoclonal antibody (“mAb”) therapies, including stability at high temperatures, potential for more effective and convenient routes of administration, and uniquely strong binding affinity. They have superior specificity and affinity to particular targets, potentially enabling lower doses, hence lowering cost and reducing adverse side effects, if any. Moreover, NanoAbs are hyper-thermostable, a property that prolongs their shelf life and eases storage and distribution. Perhaps most importantly, NanoAbs exhibit potential as ‘biobetter’ therapies for a wide range of diseases with known and validated antibody drug targets, a strategic approach expected to shorten development timelines while increasing the probability of drug approval.

Speaking during an episode of the Test. Optimize. Scale. podcast, Amir explained that the strategic selection of both an antibody-based technology (NanoAbs) and indications with validated antibody drug targets prevents the company from reinventing the wheel (https://ibn.fm/ulg3u). Certain antibodies are already known to generate a good clinical response whenever they are used to attack a target molecule. Thus, according to Reichman, Scinai Immunotherapeutics’ strategic approach is expected to shave off $200 million and seven years of drug development.

In addition to its ongoing R&D and to bolster recurring revenue, the company has rolled out boutique end-to-end Contract Development and Manufacturing Organization (“CDMO”) services under the banner Scinai Bioservices. Intended to serve biotech, pharmaceutical, and alternative protein food tech companies with pilot and clinical process development and manufacturing, the division will leverage SCNI’s cGMP manufacturing facility, state-of-the-art laboratories, and deep pharma experience.

“There is growing demand by small biotech companies seeking high quality, yet affordable CDMO services to accelerate their drug development processes, including cGMP aseptic processing required for manufacturing of clinical batches. Scinai’s state-of-the-art biologics facility and team’s capabilities and extensive experience are a perfect match for these clients,” said Reichman in a press release announcing the finalization of a major rebrand (https://ibn.fm/lsGuY).

The company’s management is optimistic about SCNI’s growth potential and ability to deliver value to its stakeholders. “We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership, and an expertly designed technological base,” concluded Reichman.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

• Rare earth supply chain innovator Ucore Rare Metals Inc. is working to strategically develop a North American-based supply chain for rare earth elements (“REEs”) that are vital to technologies ranging from smartphone to F-16 fighter jet parts
• China currently has a near-monopoly on REE refining and production, and international tech trade tensions in recent years have pushed Western nations to seek ways to revive their own REE industries
• Ucore has developed a proprietary RapidSX(TM) REE separation technology platform for refining rare earths, beginning with a strategic facility in development in Louisiana
• The company is celebrating announcement this month that it has completed the process for obtaining an 80 percent tax exemption for the next decade, pending the governor’s ratification of state and local authorities’ approvals

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a strategic metals supply chain-focused enterprise, is celebrating its advancing rare earth element (“REE”) project in Louisiana with the recent announcement that the company has received approvals from the Industrial Tax Exemption Program (“ITEP”) that will result in significant cost savings to Ucore.

Ucore has entered a multi-decade lease agreement with the administrators of the England Airpark in Alexandria, La., that will allow Ucore to build and operate a Strategic Metals Complex (“SMC”) where it will separate and produce REEs and oxides that are deemed critical to computer technology-based industries.

Currently, REE mining and refining are controlled by The People’s Republic of China to a degree that approaches a virtual monopoly. The European Union imports 98 percent of its REE supply from China and the United States gets 78 percent of its REE supply from China.

The industrial espionage and trade limit tensions of recent years between the United States and China have given rise to renewed efforts to maintain a Western hemisphere center to the supply chain for REE elements used in products ranging from cell phones to electric vehicles to F-35 fighter jets.

Ucore’s advancing SMC complex in Louisiana is central to the company’s plan to build that Western supply chain, starting with the refining of mined product.

“The overall State and local support we are receiving for the establishment of one of the first modern rare earth element processing facilities in North America has been an amazing experience, and we are diligently working to execute a Louisiana project that has the potential to significantly enhance the manufacturing landscape across North America as the world shifts to electrification,” Ucore Vice President and COO Mike Schrider stated in the company’s announcement about the tax exemption progress (https://ibn.fm/IzvFB).

According to the news release, the ITEP program offers up to a 10-year exemption to the company of 80 percent of the standard tax amount on a renewable five-year term, which may result in $8.2 million in projected tax savings for the company if the governor gives his final signature to the agreement.

Louisiana and the local parish have awarded the exemption based on Ucore’s commitment to create 100 family-wage paying jobs, its plans to make a capital investment of $75 million in the economy, and expectations that further statewide benefits for workers will be realized.

The company has been simultaneously engaged in establishing agreements for raw material supplies and supply off-take, as well as other financial arrangements.

The SMC complex will use Ucore’s proprietary RapidSX(TM) REE separation technology platform in a commercialization venture. RapidSX(TM) promises to improve on the industry standard for REE refining in terms of speed, environmental impact, and eventual cost factors. The company plans to produce 2,000 metric tons per year of total rare earth oxides (“TREOs”) by the beginning of 2025, growing to 5,000 tons by 2026 and 7,500 tons in 2027.

The company also owns an Alaskan rare earth mine prospect that it may eventually bring online to add to the limited American-based REE feedstock that currently exists.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Eloro Resources recently published its initial NI-43101 compliance mineral resource estimate (“MRE”)
• The company’s long-awaited MRE revealed the existence of total inferred mineral resources amounting to 670 million tonnes – equivalent to nearly $6.8 billion in value
• Whilst impressive, Eloro’s management has revealed that the company has more exploratory drilling work to continue towards the site’s western edge, with further mineral resource estimate enhancement remaining likely

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company focused on developing its potential world-class Iska Iska silver-tin polymetallic property located in the Potosi Department in southern Bolivia, recently updated the market with its initial mineral resource statement. Prepared in conjunction with mining consultancy Micon International Limited, Eloro announced that its exploratory drilling work had uncovered the existence of a ‘giant deposit’, amounting to nearly 300 million ounces of in situ silver, 4.1 million tonnes of zinc, 1.74 million tonnes of lead and 130,000 tonnes of tin boasting a cumulative in situ value of approximately $6.8 billion (https://ibn.fm/Hl4Yh). Interestingly, the company’s MRE attributed a value of $3.3bn to minerals located within the shallower, high-grade zone within the potential open pit, opening up the possibility of an earlier payback period than originally anticipated (https://ibn.fm/OkOdr).

Tom Larsen, CEO of Eloro, said: “We are delighted with this initial MRE which shows what a massive discovery Iska Iska is. The recent metallurgical work, particularly the positive “ore sorting” results, has significantly enhanced the potential economics by substantially lowering the NSR cutoff, especially for the potential open pit where the bulk of the resource is located. The fact that this potential pit is 1.4km in diameter and extends to a depth of 750m below the Santa Barbara hill attests to the remarkable size of the Iska Iska mineralized system.”

Larsen went on to additionally elaborate how the ongoing drilling work and subsequent initial mineral resource estimate publication was only a partial representation of the Iska Iska property’s total resources. Recent drilling at the adjoining Casiterita site, located 2km south-west of the original Santa Barbara zone returned a 0.17% presence of tin over 52.78m, implying that the overall extent of the Iska Iska mineralizing system was far more extensive than originally implied by the geophysical data. In particular, the company’s management went on to emphasize how the potential tin domain west of the original exploratory site remained extremely under-explored and would be subject to further testing during the next phase of drilling.

“Our geological team led by Dr. Bill Pearson, P.Geo., Vice President, Exploration, and Dr. Osvaldo Arce, P.Geo., General Manager of Minera Tupiza, are confident that the Iska Iska resource can be further expanded and that grades in areas with only wide-spaced drilling will likely increase with definition drilling. The tin domain in particular is very under-drilled, and our geophysical data indicates potential for a large tin porphyry at depth.”

Bolivia’s Cerro Rico de Potosi region has long been renowned for its prolific silver and tin deposits, with active mining operations carried out within the region dating as far back as the sixteenth century.  The recent discoveries at Iska Iska – a site nestled within Potosi’s fertile hills and product of a longstanding process that commenced with Eloro Resources exercising its option agreement to acquire the polymetallic property in early 2020 – holds great promise at a time when minerals such as tin and silver continue to enjoy skyrocketing demand – a result of the world’s ongoing drive towards renewable energy adoption. With its NI-43101 report now published and further exploratory drill work set to commence, Eloro Resources looking increasingly well-placed to capitalize on the increasingly insatiable demand for the minerals fuelling today’s global energy transition.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Prospera in 2021 launched a new strategy to improve margins and oil and gas production while minimizing environmental impact
• Horizontal well-technology allows for increase in production and Prospera has now abandoned 60 vertical wells as part of its three-year LMRP to reclaim surface land and reduce environmental footprint that will see 200+ vertical wells abandoned
• Prospera this month completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program that can add an additional ~750 bpd at a low decline to Prospera’s current 900+boepd

With more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta, Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) has the potential to be a significant North American oil and gas producer. In 2021, the company underwent a top-down reorganization, a strategy to realize this potential and do so with best practices regarding protecting the planet. Less than two years into the three-part plan, Prospera is hitting its key performance indicators (“KPIs”), and growing production with an eye on reducing vertical wells.

With its restructuring, Prospera incorporated innovative ESG (environmental, social, and governance) technologies to support a robust Liability Management Ration Program (“LMRP”) to reduce the environmental footprint, Asset Retirement Obligation (“ARO”), and corresponding control expenses and improve margins. LMRPs are an important tool for managing the financial risks associated with oil and gas abandonment and reclamation. They help to protect taxpayers, encourage companies to be more responsible, and ensure that wells and facilities are abandoned and reclaimed in a timely and environmentally responsible manner.

The Canadian government is supportive of LMRPs, offering financial incentives (e.g., tax credits) and loan guarantee programs to assist companies implement programs.

Prospera’s plan is working. 2021 reorganization efforts as phase one of the strategy resulted in production appreciation and liability reduction. Amongst other things, Prospera’s net asset value increased to $72 million from -$3.4 million prior to restructuring. In 2022, phase 2 of the development plan commenced, delivering net income of $3.1 million. In 2024, Prospera is targeting $26.5 million in net income.

From an environmental view, phase two includes capitalizing on Prospera’s large drilling inventory of 150+ targets that are estimated to hold more 400+ million barrels of heavy oil, with only about 9 percent recovered to date. The company has abandoned 60 vertical wells as part of its three-year LMRP that allows PEI to reclaim surface land and reduce environmental footprint. More broadly, the drilling of the new horizontal wells allows Prospera to abandon more than 200 vertical wells.

Phase three includes reducing carbon emissions with upgraded equipment, increasing carbon capture, and the latest technology to further improve profit margin.

This month, Prospera completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program. These wells, which were completed ahead of schedule, encountered structure, and paid as expected with excellent oil shown throughout the pay.

These drilled horizontals are being completed and tied-in to existing infrastructure. Production will be brought on gently initially to optimize recovery due to the heavier fluid properties. The full deliverability can be attained, approximately, over a three-month period. Weather permitting, the next set of four horizontals are to commence within one week.

The ten-well program can approximately add an additional 750 barrels per day (“bpd”) at a low decline to Prospera’s current 900+boepd (barrels of oil equivalent per day). This infill development is intended to accelerate production and recovery to capture the significant heavy oil reserves in place.

Further, a medium-light oil spud will follow the heavy oil horizontal well transformation from vertical wells in the latter part of this month. These slanted drills are awaiting the preparation of the new leases, surface facilities, and connecting pipelines. The medium-light oil development entails six to eight directional wells that can add an additional 600bpd (gross) at 50%, while diversifying Prospera’s product mix and improving margin.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• With EV sales skyrocketing around the world, securing lithium and natural graphite supplies has become a priority for battery manufacturers
• Reflex Advanced Materials has centered its efforts around catering to the lithium and graphite supply chains, with the company announcing that it had fulfilled the penultimate capital payment step needed to secure 100% ownership of its Ontario-based Zigzag lithium project
• The company also took the opportunity to announce the start of core exploratory drill work within the Montana-based Ruby Graphite project

As auto sales staged a significant recovery in the United Kingdom this summer, electric vehicles led the surge. The British Society of Motor Manufacturers and Traders (“SMMT”) revealed that a new battery electric car was registered every sixty seconds, with electric vehicle (“EV”) deliveries rocketing by 87.9 percent relative to the previous year. Moreover, the industry body forecast that new electric vehicle sales momentum would continue its meteoric rise, foreseeing that an electric vehicle would be registered every 50 seconds by year end, rising to one in every 40 by 2024 – a beneficiary of rising uptake levels for EV’s amongst automobile purchasers (https://ibn.fm/5SUjY).

The increase in electric vehicle demand has led to a proportional increase in electric battery sales; automotive lithium-ion battery demand increased by approximately 65 percent to a cumulative 550 GWh in 2022, up from 330GWh in 2021 (https://ibn.fm/YuSYD). The ongoing shift towards renewable energy technologies within the automotive industry has led to a spiraling need to ensure the supplies of key raw materials within the battery manufacturing process – with lithium and graphite ranking chief amongst these. A typical EV battery can contain upwards of 8 kilograms of lithium and up to 50-100 kilograms of graphite (https://ibn.fm/L1WYT); Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), a British Columbia-based strategic minerals company has centered its corporate mission around locating and developing economic properties within the advanced materials space to cater to the rapidly growing needs of the global electric vehicle industry supply chain.

In mid-August, Reflex Advanced Materials announced that it would be issuing 100,000 new common shares of its capital, the penultimate step needed to fulfil a mineral property option payment agreement the company had entered in 2021 for its Zigzag lithium project. Located near Crescent Lake, Ontario and consisting of eight mining claims totaling approximately 2,710 hectares, the Zigzag lithium project is located deep within an area which has come to be known as the Seymour-Crescent-Falcon lithium belt (https://ibn.fm/laWTE), a geographical phenomenon which has witnessed a number of recent lithium-focused exploration successes over the past few years.

Securing a steady source of lithium has become an increasingly urgent priority for EV battery manufacturers, with Albemarle, the world’s largest lithium producer, recently warning that global lithium demand could outstrip supply by approximately 500,000 tonnes as early as 2030. Despite 45 lithium mines operating globally in 2022, with a further 11 planned to open this year, and an additional seven in 2024, incoming supply of the mineral may not be sufficient to satisfy the sector’s voracious demand.

“You could end up in a crisis situation where the battery companies don’t have the security of (lithium) feedstock,” Stu Crow, chairman of peer lithium producer Lake Resources (https://ibn.fm/0fE9r).

In addition to its lithium-focused ambitions, Reflex Advanced Materials has also sought to boost its graphite supply capacity. One of only a handful of companies catering to the western natural graphite supply chain, Reflex announced that it would shortly begin mobilizing drill equipment for its planned Summer 2023 initial drill program at the Ruby Graphite project in Montana. The Ruby Graphite project, which had earlier produced upwards of 2,400 tons of graphite between 1902 and 1948, will see Reflex carry out over 3,500 meters of core exploratory drill work, with the company announcing that preparatory drill pad construction was already underway (https://ibn.fm/f4l6g).

Paul Gorman, CEO of Reflex Advanced Materials, expressed his enthusiasm about the upcoming drilling campaign, stating, “The mobilization of drill rigs marks an important milestone for Reflex as we advance our exploration efforts at the Ruby Graphite project. We are confident that this drill program will not only confirm the presence of high-grade graphite based on the historical commercial production from the historical Crystal Graphite mine which operated within the current Ruby Graphite project before 1948, but also provide proof-of-concept for moving forward with this important critical and strategic resource.”

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• SenesTech, with its proprietary biological solution for efficiently and safely reducing rat populations without killing, represents a remarkable new path to clean cities, businesses, and households
• According to pest industry figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States
• ContraPest offers a unique solution for wastewater facilities because it is non-poisonous and comes in a variety of formats that can help control rat populations where other approaches fall short

SenesTech (NASDAQ: SNES), the rodent fertility control experts and the inventor of the only EPA-registered contraceptive for male and female rats, recently announced that its ContraPest(R) is being deployed in Washington and California through wastewater treatment facilities. Controlling rat infestations presents a unique challenge for wastewater treatment facilities because poisons cannot be introduced into the water supply, and ground-based stations may not be appropriate for many of the facilities.

“Municipalities and government entities comprise a broad and diverse customer base. We are continuously working with these customers, and the pest management professionals who service them, to understand their specific needs and to guide them as to how best to add ContraPest to their integrated pest management system,” said Joel Fruendt, President and CEO of SenesTech (https://ibn.fm/OxgPz). “Wastewater treatment deployment has very specific challenges, and we are able to develop and share deployment protocols utilized by other, similar customers.”

SenesTech strives for clean cities, efficient businesses, and happy households with a product scientifically designed to be effective without killing rats. The company’s first product, ContraPest, applies revolutionary technology to a challenge that has plagued the world since the Middle Ages – the increase of rat populations in urban and agricultural settings. The ContraPest formulation is a highly palatable liquid promoting sustained consumption. It targets the reproductive capabilities of Norway and roof rats, reducing fertility in both male and female rats, bringing populations down, and keeping them down.

SenesTech’s flagship offering, ContraPest, can be used as part of an integrated pest management (“IPM”) program – fitting seamlessly into all IPM programs, reducing reproduction, and magnifying the success of these protocols. It can also be used as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods. ContraPest reduced rat activity by up to 95% in multiple independent field deployments when added to an existing IPM program.

The global rodenticides market is expected to reach a revenue of $7.1 billion by 2027, growing at a CAGR of 5.8%. The market’s growth is attributed to the rising concern for environmental pollution and public health hazards posed by vector-borne diseases, fueling the global demand for rodent control services. The growing population, limited resources, and ecosystem degradation are factors that contribute to the rodents’ ability to survive in different seasons and overpopulation (https://ibn.fm/KrIW0).

Rats are known to spread at least 35 diseases, posing a dangerous risk to public health and safety across the globe. This problem persists despite extensive campaigns to eradicate it, and multiple sources have reported a boom in post-COVID rat populations. Although poison-based control methods sicken rats, they die slowly – and when an animal eats these infected rats, it can also make that animal sick.

ContraPest is available in three unique bait systems – the Ultimate Bait System(TM), Elevate Bait System(TM), and Isolate Bait system(TM). The active ingredients in ContraPest are specifically formulated for rats and break down in their digestive system, resulting in no bioaccumulation or biomagnification in the environment.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals
• The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs
• Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks
• Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of psoriasis, psoriatic arthritis, asthma, macular degeneration, and Hidradenitis Suppurativa
• The company is intensifying its pipeline development, identifying additional opportunities, and developing novel solutions for large-market unmet needs in 2023 and beyond

When Amir Reichman took over the reins as CEO of the then-named BiondVax Pharmaceuticals in March 2021, he and the Board of Directors embarked on redefining the biotechnology company’s mission and vision. “Our new mission reflects an aspiration to focus on infectious diseases, which leverages [the company’s] core competencies, while ensuring fdiversification of our corporate risks through the establishment of a new, broad product and platform pipeline,” shared Reichman in his first letter to shareholders (https://ibn.fm/oyYwX).

Reichman expressed his intent to rejuvenate the company by implementing a strategy that would diversify the risk along four main axes, including building a pipeline of products for both prevention and treatment of infectious diseases and related illnesses; building a pipeline that would present various routes of drug delivery; building a pipeline that would rely on various platforms; and building a pipeline of products at different stages of clinical development. “If successfully implemented, this strategy would provide [the company] with a robust and diverse multi-dimensional pipeline,” continued Reichman.

Over the two years since that initiation, the company has revamped its senior management team and pharmaceuticals development programs. Additionally, as part of its diversification strategy, the company has expanded into the Contract Development and Manufacturing Organization (“CDMO”) business. Together, these changes represent a fresh start for the company as it journeys toward a new strategic objective. As part of this journey, the company also recently finalized a major rebrand, debuting as Scinai Immunotherapeutics (NASDAQ: SCNI) on Nasdaq as of September 7 this year (https://ibn.fm/5Op2c).

“The biotech sector has been through an extremely challenging time in the past 18-24 months, with low stock prices and scarce capital. We have nevertheless made tremendous progress executing our turnaround program with limited resources and believe we are at the cusp of building a significant and successful company,” commented Reichman in the news release. “We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership, and an expertly designed technological base. Building on promising data of our initial NanoAb therapies, we look forward to continuing our current pipeline development and also identifying additional opportunities and developing novel solutions for unmet needs in 2023 and beyond.”

Anchoring Scinai’s renewed commercial focus and pipeline development is a robust collaboration with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (“MPI”), and the University Medical Center Göttingen (“UMG”), both in Germany, to develop innovative alpaca-derived nanosized antibodies (“NanoAbs”) (https://ibn.fm/Y1e4d).

The NanoAbs are approximately one-tenth the size of standard monoclonal antibodies (“mAbs”) and are designed to overcome the limitations of existing antibody therapies. For instance, NanoAbs may be effective at extremely low concentrations, which translates to fewer side effects. Moreover, they are expected to have better tissue penetration because of their small size and have demonstrated superior thermostability, which, according to Scinai, could translate to superior shelf life, easier transportation, and more convenient routes of administration. These favorable and unique attributes bolster the company’s efforts to create ‘biobetter’ therapeutics that address large and underserved markets.

In early June, Scinai, in exercise of its broad-based collaboration agreement with Max Planck Society and UMG, signed an exclusive worldwide license agreement to develop and commercialize NanoAbs targeting interleukin-17 (“IL-17”), an immune system cytokine, as treatments for all potential indications, including psoriasis, psoriatic arthritis, and Hidradenitis Suppurativa (https://ibn.fm/twpTX). Beyond that, the company’s NanoAb development pipeline also includes anti-IL-13 and anti-TSLP therapeutics for the treatment of asthma and anti-Ang-2 and anti-VEGF therapeutics for the treatment of age-related wet macular degeneration.

This pipeline approach, Scinai says, affords it considerable flexibility with respect to partnering and extending its assets, opening enhanced potential to generate income through license fees, milestone payment, and royalties, in return for participation in associated R&D costs. To complement its R&D operations, the company also launched Scinai Bioservices, a new business unit that will provide a multitude of CDMO services to support biotechnology companies through process development and GMP manufacturing.

“I’d like Scinai to be internationally recognized for scientific excellence in drug development that is done in the fastest, sharpest way and with the highest quality possible. I want Scinai to be the go-to company for large multinational companies seeking innovative technology and partners that excel in drug development and that can bring their return on investment much faster,” shared Reichman in a video published recently on the company’s YouTube channel (https://ibn.fm/HjOl7).

The name change only reinforces the mission and commitment of Jerusalem-based Scinai Immunotherapeutics to develop, manufacture, and commercialize potential blockbuster immunotherapeutic products for the treatment of infectious diseases and autoimmune disorders. Expect to hear lots more from this innovative biotech company in the months to come.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

• Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades
• PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism
• Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials
• In 2024, we’re poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program
• With NDA approval, we anticipate the potential to secure a valuable Priority Review Voucher (“PRV”) that could expedite our journey toward FDA recognition for Autism treatment
• Vigorous preparations are underway for clinical trials of PAX-101 in Autism, marking a significant step forward in our mission

In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This disorder has seen a fourfold increase over the past two decades, underscoring the urgency of PaxMedica’s mission.

PaxMedica stands alone as the only publicly traded company in the U.S. with an unwavering focus on ASD. Weisman highlights the dedication and commitment of the entire PaxMedica team to confront the unique challenges of autism head-on.

Click Here to View the Video 

Weisman further emphasizes the company’s groundbreaking lead product, PAX-101. Early trials of PAX-101 have shown remarkable promise in reducing the core symptoms of Autism, offering newfound hope to countless families affected by this condition.

Looking to the future, PaxMedica has ambitious plans. The company is preparing for an NDA submission of PAX-101 for the treatment of Human African Trypanosomiasis (“HAT”), also known as African Sleeping Sickness, scheduled for 2024. This effort falls under the Neglected Rare Tropical Disease Program, and if approved, could pave the way for PaxMedica to receive a highly valuable Priority Review Voucher (“PRV”), expediting its path to gaining FDA approval for Autism indication.

As PaxMedica prepares for clinical trials of PAX-101 for Autism, Weisman and his team are unwavering in their commitment to bring about transformative change for individuals and families affected by ASD. With optimism and dedication, PaxMedica is focused on delivering innovative solutions and a brighter future for those touched by autism.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD